We use cookies to understand how our site is used so we can improve it. Necessary cookies are always on. You can accept all, reject all, or choose what to allow. Learn more
Beauty & CosmeticsFirst to the category, late to the wave: how Korea's original clean-beauty brand handed a private-equity owner a profit it could fix in a quarter — and a growth problem it may not
Beauty & Cosmetics
First to the category, late to the wave: how Korea's original clean-beauty brand handed a private-equity owner a profit it could fix in a quarter — and a growth problem it may not
Manyo Factory helped invent the clean/vegan, one-hero, export-online playbook that built K-beauty's breakout brands. Then a later cohort ran that same playbook to two-to-three times its scale while Manyo went flat. In 2025 a private-equity sponsor reset the cost base and the operating margin snapped back to 22.5% in a single quarter. The harder question — the one an acquirer is really underwriting — is whether anyone can manufacture a second hero before the cost savings run out.
Clean, vegan, ingredient-led skincare — the category Manyo Factory helped open in Korea in the 2010s. A decade later the same playbook built bigger brands, and the pioneer is now being professionalised by a private-equity owner.
In the 2010s, before 'clean beauty' was a phrase anyone in a Western department store used, a small Seoul company called Manyo Factory was already selling it. Its hero was an unglamorous one: a plant-oil makeup remover, the Pure Cleansing Oil, that Korean shoppers turned into a national staple. It has since sold something on the order of 22 million bottles and has been Olive Young's number-one cleanser for five straight years. Manyo helped open Korea's clean, vegan, ingredient-led category before the term was common.
Being early, it turns out, is not the same as owning it. The playbook Manyo helped write — one clean hero product, sold direct and online, exported brand-first — is exactly the playbook a later cohort of Korean indies used to build far bigger businesses: Anua, Beauty of Joseon, d'Alba, APR. Over the same recent years those brands compounded two-to-three times while Manyo's revenue went flat and then fell. And in April 2025 the story took a sharper turn: a private-equity firm bought control and began, deliberately, to take the company apart and put it back together.
The cost reset is already visible in the numbers. Whether the brand can also re-accelerate its top line is the open question this analysis is built around.
A reset, not a restart
On the surface, FY2025 looks like distress: revenue down 11.6% to ₩113.0bn and operating profit down more than 40%. The company's own filings say otherwise, and name the causes. The new owner — the private-equity firm KL&Partners, which took a 51.87% stake in April 2025 — deliberately cut the company's China-heavy revenue to improve quality (Asia revenue fell about 21% while North America grew 39.7%), and the year absorbed one-off costs: severance for the departed founder-era management and a headquarters move. The decline was, in large part, engineered.
Five years of margin erosion, then a reset. Revenue grew and then dipped — but the story is the operating-margin line: a pre-IPO peak near 28% ground down to 9.3% by FY2025, the year a new owner cleared the decks.Source: Manyo Factory consolidated financials, DART (FY2021–FY2025; FY2021–22 pre-IPO comparatives). In 1Q 2026 the operating margin rebounded to 22.5% — the first proof point of the reset.
One quarter into the new fiscal year, the reset showed up where it matters. In 1Q 2026 revenue was essentially flat (up 0.2% at ₩26.9bn) but operating profit rose 326% to ₩6.05bn, lifting the operating margin to 22.5% from a 5.3% trough a year earlier. There is a caveat worth keeping in view: Korean trade analysis attributes much of the jump to a roughly ₩2.6bn cut in advertising — profitability restored by spending less, while revenue stayed flat. That is the right first move in a value-up. It cannot be the whole plan, because the US and Japan build the sponsor is also attempting requires marketing, not less of it.
One hero carries the house
Manyo is not a portfolio of equally weighted brands; it is one brand and, within it, one franchise. The Pure Cleansing Oil sits in genuinely differentiated white space — the cleansing-oil lane, rather than the crowded toner, snail-mucin or cushion lanes the export-native indies fight over. The second pillar is the Bifida Biome Complex Ampoule, and the company is now pushing up the efficacy ladder into brightening (a Glutathione line, a Galac-Niacin essence) and colour (the Nomercy brand) to broaden beyond the single hero. The bull case is that cleansing is a defensible, repeat-purchase consumable with a five-year ranking moat; the bear case is the one the Korean trade press states plainly — that the company 'has not produced a big hit since the cleansing oil.'
The Pure Cleansing Oil is the asset. A single plant-oil cleanser — Olive Young's #1 for five consecutive years — anchors a category that is roughly 58% of Manyo's revenue.
Category (FY2025)
Revenue
Share of revenue
Cleansing
₩65.9bn
58%
Ampoule & Serum
₩22.8bn
20%
Skincare
₩16.1bn
14%
Merchandise & other
₩8.2bn
~7%
Source: Manyo Factory FY2025 annual report, DART (rcept 20260323001497). A single category, anchored by a single hero SKU, is the majority of the business — the concentration that makes 'a second hero' the central question.
Asset-light: a marketer that outsources the factory
The structural fact that defines Manyo's margins, its speed and its risks is that it manufactures nothing. The company procures its formulations from OEM/ODM partners — the same Korean contract-manufacturing backbone (Cosmax, Korea Kolmar, Cosmecca) that the entire indie-export wave rides — and buys only the primary packaging. That buys speed and capital efficiency: no plant, no manufacturing capex, fast SKU iteration. It also means the moat is brand and channel, not technology. R&D is just 0.2% of sales and falling; the formulations originate with shared partners, so the defensibility is the name on the bottle, not proprietary IP — exactly the device or formulation moat that rivals like APR have and Manyo does not.
Cash & deposits vs. interest-bearing debt (FY2025)
₩100.7bn / ₩0
Against ₩122.7bn of equity, with a current ratio above 1,700%. The balance sheet can fund a US/Japan build and a share buyback at the same time, without leverage — the structural pre-condition for the value-up.
One unusual data point underlines that the brand equity is real. Korean customs reportedly detected 952 counterfeit Manyo products in the latest reference year — more than the 812 found for Sulwhasoo — making Manyo the most-counterfeited K-beauty skincare brand in that dataset. Counterfeiting is a cost and a brand risk, but it is also a revealed-demand signal: counterfeiters target what sells.
Olive Young is the discovery engine Manyo already wins at home — its #1 cleanser ranking is the franchise's clearest proof of pull. The harder shelf to win is the one abroad.
The wave Manyo helped start — then missed
Manyo's reset is happening into a tailwind. Korea's cosmetics export engine set back-to-back records, and — critically for Manyo's strategy — its centre of gravity moved exactly where the company is now pointing: away from China and toward the US, Japan and a long tail of new markets. Total exports hit a record of roughly US$11.4bn in 2025, ranking Korea the #2 cosmetics exporter globally behind only France. The structural shift underneath is the part that matters: China fell from about US$3.8bn in 2020 to US$2.0bn in 2025, while the US tripled and overtook China as the #1 destination for the first time. Skincare — Manyo's category — was roughly 75% of the mix. The decision to cut China and grow North America was swimming with the tide, not against it.
Korea cosmetics exports, 2025 — a record, and a #2 global ranking
≈US$11.4bn
The US overtook China as the #1 destination for the first time, and skincare was ~75% of the mix — the macro is moving toward exactly the geography and category Manyo is now chasing.
The deliberate pivot, in one picture. Total revenue dipped in the reset year — but the export share of that revenue climbed to 60%, the visible fingerprint of cutting low-quality China volume in favour of overseas demand.Source: Manyo Factory FY2025 annual report, DART (§4 revenue table). Domestic revenue fell harder than export revenue in FY2025, lifting export share to 60.0% even as the total shrank.
The competitors who scaled the same playbook
The K-beauty competitive set bifurcated sharply over FY2023–25. The export-native indies and the device/platform players compounded two-to-three times; the legacy and one-hero brands stalled. Manyo's defining competitive fact is uncomfortable: among the direct premium-indie analogs, it is the only one — alongside the colour house Clio — to have printed a revenue decline while the wave ran. The closest analog, d'Alba, grew from ₩200.8bn to ₩519.7bn (×2.6) on a single premium hero distributed through aggressive global online. APR pairs an AGE-R device line with Medicube consumables — a razor-and-blades ecosystem Manyo's cleansing oil cannot match. Silicon2, the export distributor, captures the wave's value at the infrastructure layer and wins regardless of which brand is hot.
Company (KOSDAQ/KOSPI)
FY23 rev
FY25 rev
CAGR
FY25 margin
Hero / model
Manyo Factory (439090)
₩105.0bn
₩113.0bn
+3.7%
9.3%
Cleansing oil; clean/vegan
APR (278470)
₩523.8bn
₩1,527.3bn
+70.8%
23.9%
AGE-R device + Medicube
Silicon2 (257720)
₩342.9bn
₩1,116.3bn
+80.4%
18.4%
Export distributor/platform
d'Alba (483650)
₩200.8bn
₩519.7bn
The unsolved problem is here, not at home: an Amazon/TikTok ranking and a US retail footprint (an Ulta entry began in 2026) deep enough to move the total — built against incumbents who already have one.
“Manyo helped invent the clean/vegan, hero-SKU, export-indie playbook — then watched a later cohort execute it at greater scale. Being early to a category is not the same as owning it; the question is whether a pioneer's credibility and a fortress balance sheet can be converted into a defensible second act.”
— Nathan Research Group, Consumer Beauty Series N°01
What an acquirer is really underwriting
Strip the narrative back and the forward question reduces to one variable Manyo has not yet solved: can the value-up manufacture top-line growth, or only defend margin? The asymmetry is favourable for a value-oriented buyer. The downside is cushioned — by net cash, no debt and a still-profitable core that is cash-generative even in the bear case. The upside requires only one thing to go right: a single scalable hero in the US, which the peer set proves is achievable for a brand with Manyo's category credibility and balance sheet. The spread between the base and bull cases is almost entirely 'US execution plus a second hero.'
FY2030 scenario
Revenue
Op. margin
Revenue CAGR
What it assumes
Bull · the restart works
~₩220–280bn
18–22%
14–20%
A second hero lands and a US Amazon breakthrough makes the US and Japan real revenue legs; Manyo migrates toward the winners' band.
Base · a profitable mid-cap
~₩140–160bn
13–16%
4–7%
The reset holds and the US/Japan grow modestly off the cleansing/ampoule franchise, but no breakout hero arrives.
Bear · consolidation fodder
~₩90–110bn
8–12%
flat to neg.
No second hero; cost cuts starve the brand, the US push stalls, and Manyo is eventually absorbed by a consolidator at a modest value.
Illustrative analytical constructs to frame diligence, not forecasts of record — each defined by its assumptions, anchored to the FY2025 base, the 1Q 2026 run-rate and peer growth analogs. The base case is the most likely; the spread to the bull case is almost entirely US execution and a second hero.
Hero durability and the second act — is cleansing-oil repeat-purchase and shelf-rank actually holding under the rebrand, and do glutathione / Galac-Niacin / Nomercy show early sell-through?
US/Amazon economics behind the Ulta headline — Manyo's real US rank, customer-acquisition cost, repeat rate and channel margin, and how dependent the US business is on a rival's distribution rather than an owned position.
The margin-versus-growth trade-off — can management re-accelerate revenue while holding a mid-to-high-teens margin, or did the 1Q'26 margin come at the cost of the demand generation the build needs?
Sponsor intent — KL&Partners' hold period, return target and preferred exit, the single variable that most shapes strategy and what an acquirer inherits, and the one least visible from outside.
Contingencies — an ex-CEO ₩2bn lawsuit, counterfeiting exposure, ODM capacity and lead-time security, and US tariff sensitivity.
That is the shape of the asset. Manyo Factory is priced by the public market as a bear case — shares trade below their ₩16,000 IPO price and sell-side analysts have largely stopped covering the name — capitalised as a base case, and optioned on a bull case: a debt-free pioneer whose floor is protected and whose ceiling depends on whether a capable sponsor can manufacture a US hero before the cost reset's gains fade. The filings establish the shape of the business; the decisions that separate the base case from the bull and bear turn on facts that are not in any document. Nathan Research Group has specialised in the Korean economy since 2013, and the most interesting situations are often the ones the market has stopped watching. Our full 28-page due-diligence brief — the evidence base, the methodology and the open questions — is available to download with this article.
Listed-peer audited financials (consolidated, OpenDART, FY2023–25); CAGR and operating margin computed from those figures. Read across the row: in a reset year Manyo's 9.3% margin is below the winners, but the real gap is scale and growth — its revenue is a fraction of d'Alba's or VT's and an order of magnitude below APR's and Silicon2's.
